{Reference Type}: Journal Article
{Title}: The relationship between follicle-stimulating hormone and metabolic dysfunction-associated fatty liver disease in men.
{Author}: Bin DH;Liu F;Peng KP;Zhan M;Tan Y;Liu Q;Tang W;Mo ZN;Peng XJ;Tian GX;
{Journal}: Nutr Diabetes
{Volume}: 14
{Issue}: 1
{Year}: 2024 07 11
{Factor}: 4.725
{DOI}: 10.1038/s41387-024-00314-1
{Abstract}: The present study aimed to investigate the relationship between male hormones and metabolic dysfunction-associated fatty liver disease (MAFLD) in males.
Data from the Fangchenggang Area Male Health and Examination Survey (FAMHES) were used to analyze the male hormone levels between MAFLD patients and controls. Univariate and multivariate logistic regression analyses were performed to identify risk factors for MAFLD. Receiver operating characteristic curve analysis was used to assess the diagnostic performance of male hormones for MAFLD.
A total of 1578 individuals were included, with 482 individuals (30.54%) of MAFLD, including 293 (18.57%) with mild disease and 189 (11.98%) with moderate-to-severe disease. The MAFLD patients were significantly older than those without MAFLD. The LH, FSH, and SHBG levels in the MAFLD patients were significantly greater than those in the control group. Age, FSH, LH, SHBG, and estradiol were all risk factors for MAFLD. Age, FSH, and LH were risk factors for moderate-to-severe MAFLD. FSH was an independent risk factor for MAFLD and moderate-to-severe MAFLD. FSH showed an excellent diagnostic value, with an AUC of 0.992 alone and 0.996 after adjusting age.
Our findings indicate that FSH may be a potential diagnostic and predictive biomarker for MAFLD.